EUVIMEDEUVIMED entdecken
Crossref

Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes

Ciara L Freeman iD, Jerald Noble, Meghan Menges, Ricardo Villanueva, Justyn Y Nakashima iD, Nicholas B Figura iD, Rolf Petter Tonseth iD, Dietrich Werner Idiaquez iD, Lawrence Skelson, Eric Smith, Julieta Abraham-Miranda, Salvatore Corallo iD und 16 weitere

Blood · 10.04.2025 · 145 (15) · 1645-1657

DOI: 10.1182/blood.2024024965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 10.04.2025. Verfasst von Ciara L Freeman und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Hauptthemen laut MEDLINE: B-Cell Maturation Antigen, Multiple Myeloma, Tumor Burden, Immunotherapy, Adoptive. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a breakthrough treatment for relapsed and refractory multiple myeloma (RRMM). However, these products are complex to deliver, and alternative options are now available. Identifying biomarkers that can predict therapeutic outcomes is crucial for optimizing patient selection. There is a paucity of data evaluating the utility of both serum soluble B-cell maturation antigen (sBCMA) levels and metabolic tumor volume (MTV) at baseline in patients with RRMM undergoing CAR-T therapy. We identified a cohort of 183 patients with available serum to measure sBCMA and/or pretreatment MTV, derived from positron emission tomography–computed tomography scans obtained per standard of care. Expectedly, high pretreatment levels of sBCMA correlated with other established markers of tumor burden (eg, bone marrow plasma cells and β2 microglobulin) and inflammation and were highly prognostic for CAR-T–related toxicities and inferior progression-free survival (PFS). High MTV values were also associated with shorter PFS and inferior overall survival. The poor correlation observed between these 2 measures prompted evaluation of those with discordant results, identifying that those with low sBCMA and high MTV frequently had low/absent BCMA expression on plasma cells and suboptimal response. Our findings highlight the potential utility of sBCMA and MTV to facilitate more personalized treatment strategies in the management of RRMM eligible for BCMA-directed CAR-T.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B-Cell Maturation AntigenMultiple MyelomaTumor BurdenImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansMaleFemaleMiddle AgedAgedAdultBiomarkers, TumorPrognosisPositron Emission Tomography Computed TomographyAged, 80 and overTreatment Outcome

Substanzen

B-Cell Maturation AntigenTNFRSF17 protein, humanBiomarkers, TumorReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
  • Department of Clinical Science, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
  • Morsani College of Medicine, University of South Florida, Tampa, FL.
  • Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
  • Molecular Imaging and Therapy Program, BC Cancer, Vancouver, BC, Canada.
  • Department of Hematopathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.

ORCID-Profile: Ciara L Freeman, Justyn Y Nakashima, Nicholas B Figura, Rolf Petter Tonseth, Dietrich Werner Idiaquez, Salvatore Corallo, Hien Liu, Taiga Nishihori, Kenneth H Shain, Ariel Grajales-Cruz, John M Koomen, Jongphil Kim, Yoganand Balagurunathan

Zitieren

APA

Freeman, C. L., Noble, J., Menges, M., Villanueva, R., Nakashima, J. Y., Figura, N. B., Tonseth, R. P., Werner Idiaquez, D., Skelson, L., Smith, E., Abraham-Miranda, J., Corallo, S., De Avila, G., Castaneda Puglianini, O. A., Liu, H., Alsina, M., Nishihori, T., Shain, K. H., Baz, R., …, & Locke, F. L. (2025). Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood, 145(15), 1645-1657. https://doi.org/10.1182/blood.2024024965

Vancouver

Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, et al. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025;145(15):1645-1657. doi:10.1182/blood.2024024965

BibTeX
@article{Freeman2025,
  author = {Freeman, Ciara L and Noble, Jerald and Menges, Meghan and Villanueva, Ricardo and Nakashima, Justyn Y and Figura, Nicholas B and Tonseth, Rolf Petter and Werner Idiaquez, Dietrich and Skelson, Lawrence and Smith, Eric and Abraham-Miranda, Julieta and Corallo, Salvatore and De Avila, Gabriel and Castaneda Puglianini, Omar A and Liu, Hien and Alsina, Melissa and Nishihori, Taiga and Shain, Kenneth H and Baz, Rachid and Blue, Brandon and Grajales-Cruz, Ariel and Koomen, John M and Atkins, Reginald M and Hansen, Doris K and S Silva, Ariosto and Kim, Jongphil and Balagurunathan, Yoganand and Locke, Frederick L},
  title = {Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes},
  journal = {Blood},
  year = {2025},
  volume = {145},
  number = {15},
  pages = {1645--1657},
  doi = {10.1182/blood.2024024965}
}
Kostenlos starten →